Assuming it can secure the remaining necessary approvals, the company intends commencing a Phase I clinical trial next year, which will assess the safety, tolerance and pharmacokinetics of a proprietary sublingual (placed under the tongue) cannabis extract produced by Bod's partner, Linnea SA.
read more here
Delivered by @can_nab_is
No comments:
Post a Comment